GFAP and its role in Alexander disease

被引:149
|
作者
Quinlan, Roy A. [1 ]
Brenner, Michael
Goldman, James E.
Messing, Albee
机构
[1] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England
[2] Univ Alabama Birmingham, Ctr Glial Biol Med, Evelyn F McKnight Brain Inst, Dept Neurobiol, Birmingham, AL 35294 USA
[3] Columbia Univ, Ctr Neurobiol & Behav, Dept Pathol, New York, NY 10032 USA
[4] Univ Wisconsin, Waisman Ctr, Dept Comparat Biosci, Madison, WI 53705 USA
基金
美国国家卫生研究院;
关键词
Alexander disease; inclusions; Rosenthal fiber; GFAP; delta GFAP; kappa GFAP; chaperone; alpha B-crystallin; HSP27; SAPK; Jnk; MLK;
D O I
10.1016/j.yexcr.2007.04.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Here we review how GFAP mutations cause Alexander disease. The current data suggest that a combination of events cause the disease. These include: (i) the accumulation of GFAP and the formation of characteristic aggregates, called Rosenthal fibers, (ii) the sequestration of the protein chaperones alpha B-crystallin and HSP27 into Rosenthal fibers, and (iii) the activation of both Jnk and the stress response. These then set in motion events that lead to Alexander disease. We discuss parallels with other intermediate filament diseases and assess potential therapies as part of this review as well as emerging trends in disease diagnosis and other aspects concerning GFAP. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:2077 / 2087
页数:11
相关论文
共 50 条
  • [1] GFAP mutations in Alexander disease
    Li, R
    Messing, A
    Goldman, JE
    Brenner, M
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2002, 20 (3-5) : 259 - 268
  • [2] Beneficial effects of curcumin on GFAP filament organization and down-regulation of GFAP expression in an in vitro model of Alexander disease
    Bachetti, Tiziana
    Di Zanni, Eleonora
    Balbi, Pietro
    Ravazzolo, Roberto
    Sechi, GianPietro
    Ceccherini, Isabella
    EXPERIMENTAL CELL RESEARCH, 2012, 318 (15) : 1844 - 1854
  • [3] Refining the concept of GFAP toxicity in Alexander disease
    Messing, Albee
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2019, 11 (01)
  • [4] Alexander-disease mutation of GFAP causes filament disorganization and decreased solubility of GFAP
    Hsiao, VC
    Tian, R
    Long, H
    Perng, MD
    Brenner, M
    Quinlan, RA
    Goldman, JE
    JOURNAL OF CELL SCIENCE, 2005, 118 (09) : 2057 - 2065
  • [5] A systematic review and meta-analysis of GFAP gene variants in Alexander disease
    Grossi, Alice
    Rosamilia, Francesca
    Carestiato, Silvia
    Salsano, Ettore
    Ceccherini, Isabella
    Bachetti, Tiziana
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [6] Splice site, frameshift, and chimeric GFAP mutations in Alexander disease
    Flint, Daniel
    Li, Rong
    Webster, Lital S.
    Naidu, Sakkubai
    Kolodny, Edwin
    Percy, Alan
    van der Knaap, Marjo
    Powers, James M.
    Mantovani, John F.
    Ekstein, Josef
    Goldman, James E.
    Messing, Albee
    Brenner, Michael
    HUMAN MUTATION, 2012, 33 (07) : 1141 - 1148
  • [7] A novel mutation in the GFAP gene expands the phenotype of Alexander disease
    Casasnovas, Carlos
    Verdura, Edgard
    Velez, Valentina
    Schluter, Agatha
    Pons-Escoda, Albert
    Homedes, Christian
    Ruiz, Montserrat
    Fourcade, Stephane
    Launay, Nathalie
    Pujol, Aurora
    JOURNAL OF MEDICAL GENETICS, 2019, 56 (12) : 846 - 849
  • [8] CSF and Blood Levels of GFAP in Alexander Disease
    Jany, Paige L.
    Agosta, Guillermo E.
    Benko, William S.
    Eickhoff, Jens C.
    Keller, Stephanie R.
    Koeehler, Wolfgang
    Koeller, David
    Mar, Soe
    Naidu, Sakkubai
    Ness, Jayne Marie
    Pareyson, Davide
    Renaud, Deborah L.
    Salsano, Ettore
    Schiffmann, Raphael
    Simon, Julie
    Vanderver, Adeline
    Eichler, Florian
    van der Knaap, Marjo S.
    Messing, Albee
    ENEURO, 2015, 2 (05)
  • [9] Alexander Disease: A Leukodystrophy Caused by a Mutation in GFAP
    Anne B. Johnson
    Neurochemical Research, 2004, 29 : 961 - 964
  • [10] Alexander disease:: A leukodystrophy caused by a mutation in GFAP
    Johnson, AB
    NEUROCHEMICAL RESEARCH, 2004, 29 (05) : 961 - 964